Asahi Kasei Corporation (Japan) and Beijing Strong Biotechnologies, Inc. (China) are Leading Players in the Glycated Albumin Assay Market
The global glycated albumin assay market is projected to reach USD 0.3 billion by 2028 from USD 0.2 billion in 2023, at a CAGR of 8.9% during the forecast period. Growth in the glycated albumin assay market is mainly driven by factors such as the rising prevalence of diabetes and increasing government focus on disease diagnosis.
The major players in glycated albumin assay market are Asahi Kasei Corporation (Japan), Beijing Strong Biotechnologies, Inc. (China), Diazyme Laboratories, Inc. (US), DxGen Corp. (South Korea), Weldon Biotech (India), and Hzymes Biotech (China). The market players are focusing on the research of the glycated albumin assays and including new products in the market.
To know about the assumptions considered for the study download the pdf brochure
In 2022, Asahi Kasei Corporation (Japan) led the glycated albumin assay market. The company has maintained a leading position in the market through its strong presence worldwide. The company partners with third parties to offer integrated solutions. The company’s strategy focuses on four factors: affordability, capacity, outcome certainty, and values. The firm implements tailored pricing solutions to ensure maximum patient access. The company also focuses on developing new pricing models for its customers. Additionally, Asahei strategically invests in R&D to strengthen its position in the market. For instance, the company’s R&D expenditure accounted for USD 5.1 billion in 2022. This rise in R&D spending indicates the company’s growing focus on innovation and diversification in emerging markets.
In 2022, Beijing Strong Biotechnologies, Inc. (China) was the second-largest market player in the glycated albumin assay ecosystem. It has an increased presence in Asia Pacific with a strong network and growth strategies and has a product portfolio in the glycated albumin assay market. The company focuses on increasing R&D with increased investment in innovation.
Hymes Biotech, a prominent player in the global glycated albumin assay market, secured a significant market share in the glycated albumin assay market in 2022. The company’s strong presence in China serves as a foundation for expanding its operations in emerging markets like Asia Pacific, thereby strengthening its geographical reach. The company focuses on research and development as well as expanding the manufacturing of the glycated albumin assay market. These strategic initiatives enable Hymes to secure a larger market share and strengthen its position in the glycated albumin assay market.
Related Reports:
Glycated Albumin Assay Market by Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User (Hospitals & Diabetic Care Center, Diagnostic Laboratory) & Region (North America, Europe, APAC, Latin America, & MENA) - Global Forecast to 2028
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
